☆ 4.6 Review

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Urology & Nephrology

Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Luigi Nocera et al.

Summary: This study compared the efficacy and adverse events of four immune-oncology combination therapies in patients with metastatic renal cell carcinoma. The results showed that nivolumab plus cabozantinib (N+C) might provide the most favorable overall survival (OS), while lenvatinib plus pembrolizumab (L+P) might provide the most favorable progression-free survival (PFS) and objective response rates (ORRs), and nivolumab plus ipilimumab (N+I) had the lowest toxicity.

JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Oncology

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini et al.

Summary: Treatment with pembrolizumab-axitinib may lead to aminotransferase elevations, but this can be reversed with appropriate management.

EUROPEAN UROLOGY ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease

Eric Jonasch et al.

Summary: The HIF-2α inhibitor belzutifan showed efficacy in patients with renal cell carcinoma associated with von Hippel-Lindau disease, with nearly half of the patients having an objective response to treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Sumanta K. Pal et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal et al.

Summary: In this study comparing different drug treatments for papillary renal cell carcinoma, cabozantinib was found to result in significantly longer progression-free survival compared to sunitinib, while savolitinib and crizotinib did not show an improvement in progression-free survival.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

S. Aeppli et al.

Summary: In the first-line treatment of metastatic clear cell renal cell carcinoma, experts recommended various drugs and drug combinations based on different decision criteria and parameters, with significant inter-expert variations observed. This demonstrates how data from randomized trials are implemented differently in daily practice.

ESMO OPEN (2021)

添加到收藏夹

Meeting Abstract Oncology

Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

R. J. Motzer et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.

John B. A. G. Haanen et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Sumanta K. Pal et al.

Summary: The study showed that the combination of cabozantinib plus atezolizumab has promising clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

Chung-Han Lee et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

Brian I. Rini et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Oncology

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Fahad Quhal et al.

Summary: The study performed indirect comparisons of first-line immune checkpoint inhibitor (ICI)-based combination therapies for metastatic renal cell carcinoma (mRCC), revealing the advantages and disadvantages of different therapeutic combinations. The findings suggest that combinations of ICIs and tyrosine kinase inhibitors (TKIs) may provide superior treatment options in the first-line setting, while ICI-ICI combinations could be optimal for tumors with increased PD-L1 expression.

EUROPEAN UROLOGY ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

Thomas E. Hutson et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).

Nizar M. Tannir et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

T.K. Choueiri et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

Alberto Carretero-Gonzalez et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albiges et al.

ESMO OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Urology & Nephrology

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling

Sumanta K. Pal et al.

EUROPEAN UROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015

In Gab Jeong et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Oncology

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hans J. Hammers et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Renal cell carcinoma

James J. Hsieh et al.

NATURE REVIEWS DISEASE PRIMERS (2017)

添加到收藏夹

Article Oncology

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer

T. Powles et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Oncology

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y. C. Heng et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Oncology

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study

Daniel Y. C. Heng et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced clear-cell renal-cell carcinoma

Bernard Escudier et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.